title: Vasoactive intestinal peptide enhances striatal plasticity and prevents dopaminergic cell loss in Parkinsonian rats.
abstract: Destruction of the nigrostriatal dopaminergic pathway by the administration of 6-OHDA generates an animal model of Parkinson's disease. The main characteristic of this progressive neurological disorder is the loss of the dopaminergic neurons located in the substantia nigra pars compacta (SNc). Dopaminergic inputs from the SNc innervate the medium spiny neurons of the striatum and modulate the spontaneous activity of the primary output nuclei of the basal ganglia, globus pallidus interna, and substantia nigra pars reticulata. In our previous studies, we showed that systematically administered vasoactive intestinal peptide (VIP) is effective at reversing motor deficits, decreasing neuronal cell death, and repairing the myelin sheet in parkinsonian rats. In the current study, the effects of VIP on the dendritic morphology of the striatal neurons and the number of dopaminergic neurons in the SNc were examined in 6-OHDA-lesioned rats using Golgi-Cox staining and design-based stereological methods, respectively. Adult Sprague-Dawley rats were separated into sham-operated, bilaterally 6-OHDA lesioned and lesioned + i.p. VIP-injected (25 ng/kg) groups. VIP was first injected 1 h after the intrastriatal 6-OHDA microinjection (every 2 days for 15 days). The 6-OHDA significantly decreased the total number of dopaminergic neurons, branching, and spine density of the medium spiny neurons in the striatum. VIP significantly increased the number of neurons immunostained with tyrosine hydroxylase and the density of spines without altering the branching and the total length of dendrites. In conclusion, VIP might display synaptogenetic activity by enhancing the spine density in the striatum of the parkinsonian rats.
authors.affiliation: Department of Physiology and Neurophysiology, Eskişehir Osmangazi University, 26040 Eskisehir, Turkey.
authors.forename: OrhanTansel
authors.initials: O
authors.lastname: Korkmaz
authors.forename: Hakan
authors.initials: H
authors.lastname: Ay
authors.forename: Emel
authors.initials: E
authors.lastname: Ulupinar
authors.forename: Neşe
authors.initials: N
authors.lastname: Tunçel
mesh_terms: D000818:Animals; D000978:Antiparkinson Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002452:Cell Count; D003342:Corpus Striatum / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D003712:Dendrites / Q000187:drug effects / Q000648:ultrastructure; D059290:Dopaminergic Neurons / Q000187:drug effects* / Q000648:ultrastructure; D004353:Drug Evaluation, Preclinical; D009473:Neuronal Plasticity / Q000187:drug effects*; D018696:Neuroprotective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D016627:Oxidopamine / Q000633:toxicity; D020734:Parkinsonian Disorders / Q000188:drug therapy* / Q000473:pathology; D051381:Rats; D017207:Rats, Sprague-Dawley; D013194:Staining and Labeling; D014660:Vasoactive Intestinal Peptide / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D000978:Antiparkinson Agents; D018696:Neuroprotective Agents; D014660:Vasoactive Intestinal Peptide; D016627:Oxidopamine